◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Praxis Precision Medicines Inc (PRAX) EBITDA 2018–TTM

Name: Praxis Precision Medicines Inc (PRAX) ebitda history 2018-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-08-05

Praxis Precision Medicines Inc annual ebitda for fiscal TTM was -$326 million, a decrease of 7.6% from -$303 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

PRAX Annual EBITDA

EBITDA (annual)	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
EBITDA	($326M)	($303M)	($182M)	($123M)	($215M)	($167M)	($62M)	($35M)	($26M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PRAX Quarterly EBITDA

EBITDA (quarterly)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
EBITDA	($93M)	($89M)	($74M)	($71M)	($69M)	($59M)	($52M)	($33M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EBITDA at Comparable Companies

HALO EBITDA — Halozyme Therapeutics Inc
AXSM EBITDA — Axsome Therapeutics Inc
SMMT EBITDA — Summit Therapeutics PLC
CYTK EBITDA — Cytokinetics Inc
APGE EBITDA — Apogee Therapeutics, Inc. Common Stock
PTGX EBITDA — Protagonist Therapeutics Inc

More PRAX metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow · Shares Outstanding

All PRAX financial statements → Interactive PRAX charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.